4000-520-616
欢迎来到免疫在线！(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
产品库 品牌馆 现货促销 技术交流 新闻动态 联系我们
bdbiosciences
主营：主营：医疗设备、医疗耗材、实验仪器、抗体、试剂、诊断等产品
咨询热线电话
4000-520-616
公司首页 公司介绍 产品中心 新闻动态 联系方式 在线下单
当前位置： 首页 > 产品中心 > peptide > BD Biosciences/IMK Plus/349217
商品详细BD Biosciences/IMK Plus/349217
BD Biosciences/IMK Plus/349217
BD Biosciences/IMK Plus/349217
商品编号： 349217
品牌： bdbiosciences
市场价： ¥0.00
美元价： 0.00
产地： 美国(厂家直采)
公司：
产品分类： 多肽合成
公司分类： peptide
联系Q Q： 3392242852
电话号码： 4000-520-616
电子邮箱： info@ebiomall.com
立即询价
商品介绍
Product DetailsRecommended AssayReferences

Description

The BD Simultest™ IMK Plus reagent kit is a two-color direct immunofluorescence method for enumerating percentages of the following mature (non-blast) human lymphocyte subsets in erythrocyte-lysed whole blood (LWB): T (CD3+) and activated T (CD3+HLA-DR) lymphocytes, B (CD9+) lymphocytes, helper/inducer (CD4+) and suppressor/cytotosic (CD8+) lymphocytes, and natural killer (NK) (CD16+ or CD56+ or both) lymphocytes. The helper/suppressor ratio (CD4+/CD8+) can also be determined.

Contents: BD FACS™ Lysing Solution and six BD Simultest reagents:BD Leucogate™ (CD45 FITC / CD14 PE), isotype control (IgG1 FITC / IgG2a PE), CD3 FITC / CD19 PE, CD4 FITC / CD8 PE, CD3 FITC /Anti–HLA-DR PE, and CD3 FITC /CD16 PE + CD56 PE.

Resources & Tools
SpectrumViewerDownload TDSDownload MSDSIFU
Preparation and Storage

1. For in vitro diagnostic use.

2. When stored at 2° to 8°C, antibody reagents are stable until the expiration date shown on the label. Do not use after the expiration date.

3. The antibody reagents should not be frozen or exposed to direct light during storage or during incubation with cells. Keep the reagent vial dry.

4. Incubation or centrifugation times or temperatures other than those specified can be a source of error.

5. For optimal results, stain blood samples within 6 hours of venipuncture.

6. Alteration in the appearance of any of the reagents, such as precipitation or discoloration, indicates instability or deterioration. In such cases, the reagent should not be used.

7. The antibody reagents contain sodium azide as a preservative; however, care should be taken to avoid microbial contamination, which can cause erroneous results.

  1. Aiuti F, Sirianni M, Mezzaroma I, et al. HIV-1 infection: epidemiological features and immunological alterations during the natural history of the disease. Clin Immunol Immunopath. 1989;50:S157-S165.

  2. Anderson P, Blue M-L, Morimoto C, Schlossman S. Cross-linking of T3 (CD3) with T4 (CD4) enhances the proliferation of resting T lymphocytes. J Immunol. 1987;139:678-682.

  3. Antel J, Bania M, Noronha A, Neely S. Defective suppressor cell function mediated by T8+ cell lines from patients with progressive multiple sclerosis. J Immunol. 1986;137:3436-3439.

  4. Bernard A, Boumsell L, Hill C. Joint report of the first international workshop on human leucocyte differentiation antigens by the investigators of the participating laboratories. In: Bernard A, Boumsell L, Dausset J, Milstein C, Schlossman SF, eds. Leucocyte Typing. New York, NY: Springer-Verlag; 1984:9-108.

  5. Bernard A, Boumsell L, Hill C. Joint report of the First International Workshop on Human Leucocyte Differentiation Antigens by the investigators of the participating laboratories: In: Bernard A, Boumsell L, Dausset J, Milstein C, Schlossman SF, eds. Leucocyte Typing. New York, NY: Springer-Verlag; 1984:82-108.

  6. Bernstein ID, Self S. Joint report of the myeloid section of the Second International Workshop on Human Leukocyte Differentiation Antigens. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, eds. Leukocyte Typing II: Human Myeloid and Hematopoietic Cells. New York, NY: Springer-Verlag; 1986;3:1-25.

  7. Beverley P. Production and use of monoclonal antibodies in transplantation immunology. In: Touraine J, Trager J, Betuel H, eds. Transplantation and Clinical Immunology XI. 1980:87-94.

  8. Bishop G, Hall B, Duggin G, Horvath J, Sheil A, Tiller D. Immunopathology of renal allograft rejection analyzed with monoclonal antibodies to mononuclear cell markers. Kidney Internat. 1986;29:708-717.

  9. Brodsky F. A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes. Immunogenetics. 1984;19:179-194.

  10. Cobbold S, Hale G, Waldmann H. Non-lineage, LFA-1 family, and leucocyte common antigens: new and previously defined clusters. In: McMichael A, ed. Leucocyte Typing III: White Cell Differentiation Antigens. New York, NY: Oxford University Press Inc; 1986:788-803.

  11. Dalgleish A, Beverly P, Clapham P, Crawford D, Greaves M, Weiss R. The CD4 (T4) antigen is an essential component of the receptor for the AIDS virus. Nature. December 1984;312:763-767.

  12. Dimitriu-Bona A, Burmester G, Waters S, Winchester R. Human mononuclear phagocyte differentiation antigens. I. Patterns of antigenic expression on the surface of human monocytes and macrophages defined by monoclonal antibodies. J Immunol. 1983;130:145-152.

  13. Dorken B, Moller P, Pezzutto A, Schwartz-Albiez R, Molderhauer G. B-cell antigens: CD19. In: Knapp W, ed. Leucocyte Typing IV. New York, NY: Oxford University Press; 1986:34-36.

  14. Edwards J, Durant B, Jones D, Evans P, Smith J. Di erential expression of HLA Class II antigens in fetal human spleen: Relationship of HLA-DP, DQ, and DR to immunoglobulin expression. J Immunol. 1985;137:479- 490.

  15. Eichmann K, Johnson J, Falk I, Emmrich F. Effective activation of resting mouse T lymphocytes by cross-linking submitogenic concentrations of the T-cell antigen receptor with either Lyt-2 or L3T4. Eur J Immunol. 1987;17:643-650.

  16. Engleman EG, Warnke R, Fox RI, Levy R. Studies of a human T lymphocyte antigen recognized by a monoclonal antibody. Proc Natl Acad Sci USA. 1981;78:791.

  17. Evans RL, Wall DW, Platsoucas CD, et al. Thymus-dependent membrane antigens in man: inhibition of cell-mediated lympholysis by monoclonal antibodies to the TH2 antigen. Proc Natl Acad Sci USA. 1981;78:544-548.

  18. Fitzgerald-Bocarlsy P, Herberman R, Hercend T, et al. A definition of natural killer cells. In: Ades E, Lopez C, ed. Natural Killer Cells and Host Defense. 82,8756944444444

  19. Gallagher P, Fazekas de St. Groth B, Miller J. CD4 and CD8 molecules can physically associate with the same T-cell receptor. Proc Natl Acad Sci USA. 1989;86:10044-10048.

  20. Giorgi J, Hultin L. Lymphocyte subset alterations and immunophenotyping by flow cytometry in HIV disease. Clin Immunol Newslett. 1990;10:55-62.

  21. Goyert S, Tesio L, Ashman L, et al. Report on the CD14 Cluster Workshop. In: Knapp W, Dörken B, Gilks WR, eds. Leucocyte Typing IV: White Cell Differentiation Antigens. 1989:789-794.

  22. Grabstein K, Chen Y. Cell-mediated cytolytic responses. In: Mishell B, Shiigi S, ed. Selected Methods in Cellular Immunology. New York: WH Freeman and Co; 1980:124-137.

  23. Gratama J, Naipal A, Oljans P, et al. T lymphocyte repopulation and differentiation after bone marrow transplantation: Early shifts in the ratio between T4+ and T8+ T lymphocytes correlate with the occurrence of acute graft-versus-host disease. Blood. 1984;63(6):1416-1423.

  24. Haynes B. Summary of T-cell studies performed during the Second International Workshop and Conference on Human Leukocyte Differentiation Antigens. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, eds. Leukocyte Typing II: Human T Lymphocytes. New York, NY: Springer-Verlag; 1986;1:3-30.

  25. Henry C, Mishell B, Shiigi S. Hemolytic plaque assays. In: Mishell B, Shiigi S, ed. Selected Methods in Cellular Immunology. New York: WH Freeman and Co; 1980:69-123.

  26. Herrmann F, Komischke B, Odenwald E, Ludwig W. Use of monoclonal antibodies as a diagnostic tool in human leukemia. I. Acute myeloid leukemia and acute phase of chronic myeloid leukemia. Blut. 1983;47:157-163.

  27. Jackson A, Warner N. Preparation, staining, and analysis by flow cytometry of peripheral blood leukocytes. In: Rose N, Friedman H, Fahey J, eds. Manual of Clinical Laboratory Immunology. Washington, DC: American Society for Microbiology; 1986:226-235.

  28. Jackson A. Basic phenotyping of lymphocytes: selection and testing of reagents and interpretation of data. Clin Immunol Newslett. 1990;10:43-55.

  29. Jandl J. Blood and blood forming tissues. In: Jandl J, ed. Blood Textbook of Hematology. Boston, Mass: Little Brown and Company; 1987:1-48.

  30. Jayaram Y, Hogg N. Surface expression of CD14 molecules on human neutrophils. In: Knapp W, Dörken B, Gilks WR, et al., eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989:796-797.

  31. Kan E, Wang C, Wang L, Evans R. Non-covalently bonded subunits of 22 and 28 kd are rapidly internalized by T cells reacted with Anti-Leu-4 antibody. J Immunol. 1983;131:536-539.

  32. Knapp W, Rieber P, Dörken B, Schmidt R, Stein H, van der Borne A. Towards a betterdefinition of human leucocyte surface molecules. Immunol Today. 1989;10:253-258.

  33. Knowles R. Immunochemical analysis of the T cell-specific antigens. In: Reinherz E, Haynes B, Nadler L, Bernstein I, eds. Leukocyte Typing II: Human T Lymphocytes. 1986:259-288.

  34. Kurrle R. Cluster report: CD3. In: Knapp W, ed. Leucocyte Typing IV. New York, NY: Oxford University Press; 1989:290-293.

  35. Lampson L, Levy R. Two populations of Ia-like molecules on a human B cell line. J Immunol. 1980;125:293-299.

  36. Landay A, Muirhead K. Procedural guidelines for performing immunophenotyping by flow cytometry. Clin Immunol Immunopathol. 1989;52:48-60.

  37. Lanier L, Federspiel N, Ruitenberg J, et al. The T cell antigen receptor complex expressed on normal peripheral blood CD4-, CD8-T lymphocytes. J Exp Med. 1987;165:1076-1094.

  38. Lanier L, Le A, Civin C, Loken M, Phillips J. The relationship of CD16 (Leu-11) and Leu-19 (NKH- 1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol. 1986;136:4480-4486.

  39. Lanier L, Le A, Phillips J, Warner N, Babcock G. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol. 1983;131(4):1789- 1796.

  40. Lanier L, Testi R, Bindl J, Phillips J. Identity of the Leu-19 (CD56) leucocyte differentiation antigen and neural-cell adhesion molecule. J Exp Med. 1989;169:2233-2238.

  41. Ledbetter J, Evans R, Lipinski M, Cunningham-Rundles C, RA G, Herzenberg L. Evolutionary conservation of surface molecules that distinguish T-lymphocyte helper/inducer and T cytotoxic/suppressor subpopulations in mouse and man. J Exp Med. 1981;153:310-323.

  42. Legendre C, Schiffrin A, Weitzner G, Colle E, Guttmann R. Legendre C, Schiffrin A, Weitzner G, Colle E, Guttmann R. Diabetes. 1988;37:792-795.

  43. Maddon P, Dalgleish A, McDougal J, Clapham P, Weiss R, Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell. 1986;47:333-348.

  44. Moebius U. Cluster report: CD8. In: Knapp W, Dörken B, Gilks WR, et al., eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989:342-343.

  45. Nadler L. B cell/leukemia panel workshop: Summary and comments. In: Reinherz E, Haynes B, Nadler L, ID B, eds. Leukocyte Typing II: Human B Lymphocytes. New York, NY: Springer-Verlag; 1986:3–43.

  46. Nicholson J, Jones B. Immunophenotyping by flow cytometry: its use in HIV infection. Labmedica. 1989;6:21-26.

  47. Ohno T, Kanoh T, Suzuki T, et al. Comparative analysis of lymphocyte phenotypes between carriers of human immunodeficiency virus (HIV) and adult patients with primary immunodeficiency using two-color immunofluorescence flow cytometry. J Exp Med. 1988;154:157.

  48. Perussia B, Acuto O, Terhorst C, et al. Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. II. Studies of B73.1 antibody-antigen interaction on the lymphocyte membrane. J Immunol. 1983;130:2142-2148.

  49. Perussia B, Starr S, Abraham S, Fanning V, Trinchieri G. Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. J Immunol. 1983;130:2133-2141.

  50. Perussia B, Trinchieri G, Jackson A, et al. The Fc receptor for IgG on human natural killer cells: phenotypic, functional, and comparative studies with monoclonal antibodies. J Immunol. 1984;133:180-189.

  51. Prince H, Hirji K, Waldbeser L, Plaeger-Marshall S, et al. Influence of racial background on the distribution of T cell subsets and Leu-11-positive lymphocytes in healthy blood donors. Diag Immunol. 1985;3:33-37.

  52. Reichert T, DéBruyere M, Deneys V, et al. Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopath. 1991;60:190-208.

  53. Robbins P, Evans E, Ding A, Warner N, Brodsky F. Monoclonal antibodies that distinguish between Class II antigens (HLA-DP, DQ, and DR) in 14 haplotypes. Human Immunol. 1987;18:301-313.

  54. Rowe D, Beverley P. Characterisation of breast cancer infiltrates using monoclonal antibodies to human leucocyte antigens. Br J Cancer. 1984;49:149-159.

  55. Rudd CE, Burgess KE, Barber EK, Schlossman SF. Monoclonal antibodies to the CD4 and CD8 antigens precipitate variable amounts of CD4/CD8-associated p56lck activity. In: Knapp W, Dörken B, Gilks WR, et al., eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989:326-327.

  56. Schmidt R. Monoclonal antibodies for diagnosis of immunodeficiencies. Blut. 1989;59:200–206.

  57. Schmidt RE. Non-lineage/natural killer section report: new and previously defined clusters. In: Knapp W, Dörken B, Gilks WR, et al, eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Osford University Press; 1989:517-542.

  58. Schubert J, Lanier LL, Schmidt RE. Cluster report: CD56. In: Knapp W, Dörken B, Gilks WR, et al, eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press Inc; 1989:699-702.

  59. Schwinzer R. Cluster report: CD45/CD45R. In: Knapp W, Dörken B, Gilks WR, eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press Inc; 1989:628-634.

  60. Slockbower J, Belgeri K, Bruck E, et al. Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture (H3-A2). Villanova: The National Committee for Clinical Laboratory Standards, 1984.

  61. Smolen J, Chused T, Leiserson W, Reeves J, Alling D, Steinberg A. Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus. Am J Med. 1982;72:783-790.

  62. Stites D, Casavant C, McHugh T, et al. Flow cytometric analysis of lymphocyte phenotypes in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence. Clin Immunol Immunopathol. 1986;38:161-177.

  63. Terry L, Disanto J, Small T, Flomenberg N. Differential expression of the CD8 and Lyt-3 antigens on a subset of human T-cell receptor γ/δ-bearing lymphocytes. In: Knapp W, Dorken B, Gilks W, et al., ed. Leucocyte Typing IV. New York, NY: Oxford University Press; 1989:345-346.

  64. Terstappen L, Hollander Z, Meiners H, Loken M. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leuk Biol. 1990;48:138-148.

  65. Tomkinson B, Wagner D, Nelson D, Sullivan J. Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol. 1987;139:3802-3807.

  66. van Dongen J, Krissansen G, Wolvers-Tettero I, et al. Cytoplasmic expression of the CD3 antigen as a diagnostic marker for immature T-cell malignancies. Blood. 1988;71:603-612.

  67. Warnke R, Levy R. Detection of T and B cell antigens hybridoma monoclonal antibodies: a biotin-avidin-horseradish peroxidase method. J Histochem Cytochem. 1980;28:771-776.

  68. Wofsy L, Henry C, Kimura J, North J. Modification and use of antibodies to label cell surface antigens. In: Mishell B, Shiigi S, ed. Selected Methods in Cellular Immunology. New York: WH Freeman and Co; 1980:287-304.

  69. Wolde-Mariam W, Peter J. Recent diagnostic advances in cellular immunology. Diagnost Med. 1984;7:25-32.

  70. Wood G, Warner N, Warnke R. Anti-Leu-3/T4 antibodies react with cells of monocyte/macrophage and Langerhans lineage. J Immunol. 1983;131(1):212-216.

品牌介绍
BD是世界上最大的生产和销售医疗设备、医疗系统和试剂的医疗技术公司之一。致力于提高全世界人类的健康水平。BD专注于改进药物治疗，提高传染性疾病诊断的质量和速度，推进新型药物和疫苗的研究与发现。BD公司具有强大的研发能力和世界上最棘手的多种疾病进行斗争的能力。公司于1897年在纽约成立，总部位于美国新泽西州的富兰克林湖，业务遍及全球。公司的业务可分为BD医疗、BD诊断、BD生物科学三大类，生产销售包括医用耗材、实验室仪器、抗体、试剂、诊断等产品。公司的服务对象包括医疗机构，生命科学研究所，临床实验室，工业单位和普通大众。BD has state-of-the-art facilities around the globe that provide an environment that enables our highly talented workforce to be the best at their professions. We hire associates who have a passion and commitment to advancing the world of health. We are always seeking great people to join our company on its journey to greatness.BDRat Granulocytes Pure RP-1  500ug550002BDMs Ig Kpa Lgt Chain FITC 187.1  500ug550007BDICC Fixation Buffer 100mL550011BDMs CD210 NALE 1B1.3a 500ug550019BDMs CD51 Pure RMV-7 100ug550026BDMs CD5 APC 53-7.3 100ug550037BDHu CD62E PE-Cy5 68-5H11 100Tst550041BDHu CD95 Pure EOS9.1  100ug550052BDHam IgG2 Kpa ItCl FITC B81-3 250ug550057BDMs Crry/p65 Pure 1F2 100ug550059BDMs IL-4 Recom Protein 10ug550068BDMs IL-2 Recom Protein 20ug550070BDHu IL-6 Recom Protein 10ug550072BDHu MIP-1 Bta PE D21-1351 100ug550082BDMs IgG1 PE A85-1 100ug550084BDHam IgG2 Kpa ItCl PE B81-3 100ug550086BDHu CD142 Pure HTF-1 100ug550254BDHu CD1d PE CD1d42 100Tst550256BDHu CD73 PE AD2 100Tst550258BDHu CD103 FITC Ber-ACT8 100Tst550260BDMs CD11c APC HL3 100ug550268BDMs CD72b/c Aloatg PE JY/93 100ug550270BDRat CD32 Pure D34-485 500ug550272BDRat CD32 NALE D34-485 500ug550274BDMs CD3e IHC Pure 145-2C11 1mL550277BDMs CD4 IHC Pure H129.19 1mL550280BDMs CD8a IHC Pure 53-6.7 1mL
公司介绍
BD是世界上最大的生产和销售医疗设备、医疗系统和试剂的医疗技术公司之一。致力于提高全世界人类的健康水平。BD专注于改进药物治疗，提高传染性疾病诊断的质量和速度，推进新型药物和疫苗的研究与发现。BD公司具有强大的研发能力和世界上最棘手的多种疾病进行斗争的能力。公司于1897年在纽约成立，总部位于美国新泽西州的富兰克林湖，业务遍及全球。公司的业务可分为BD医疗、BD诊断、BD生物科学三大类，生产销售包
品牌分类
HIV Reagent Kits Stem Cell Enumeration BD Multicheck™ Control Other Species Cell Separation Reagents BD Facsunt™ 控制套件 Single-Color Antibodies BD™ Stem Cell Control Kit Sample Multiplexing Reagents 纯化抗体
显示分类
联络我们
服务热线：4000-520-616
（限工作日9:00-18:00）
QQ ：1570468124
手机：18915418616
快速导航：
总部地址：
江苏省苏州市工业园区星湖街218号 苏州生物医药产业园一期（生物纳米园）A4-216(邮编：215125)
工作时间：周一至周五9:00~18:00
技术支持：
短信：18915418616
服务热线：
4000-520-616（全国）
☏  0512-67156496（苏州）
版权信息：
©  2015-2022 苏州蚂蚁淘生物科技有限公司 版权所有 中国
网站备案：
友情链接：
免责声明：
本站有部分内容来自互联网，如无意中侵犯了某个媒体 、公司 、企业或个人等的知识产权，请来电或致函告之，
本网站将在规定时间内给予删除等相关处理。
扫描二维码关注官方微信
获取最新促销及产品信息